Filing Flows › Humacyte (HUMA) › Q2 2025
Humacyte (HUMA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Humacyte (HUMA) reported revenue of $301K for the second quarter 2025 (Q2 2025) and -42% from the quarter before.
Humacyte, Q2 2025: revenue $301K, net loss $37.7M, operating cash flow −$26.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $301K | -42% | — |
| Operating profit | −$29.7M | — | — |
| Net earnings | −$37.7M | -196% | — |
| Operating cash flow | −$26.4M | — | — |
What changed
Revenue was $301K in Q2 2025, down 42% from the previous quarter. Contract revenue was the largest line at 67% of revenue.
Operating costs exceeded revenue by $29.7M, an operating margin of -9876.1%. The quarter ended with a net loss of $37.7M, after a profit of $39.1M the previous quarter.
Operating cash flow was −$26.4M. Non-cash charges added back $1.3M of depreciation and $2.3M of share-based compensation. Working capital and other items added $7.6M. Capital expenditures of $568K exceeded it, leaving free cash flow of −$27.0M.
Questions
What was Humacyte's revenue in the second quarter 2025?
Humacyte (HUMA) reported revenue of $301K for the second quarter 2025 (Q2 2025) and -42% from the quarter before.
Source: Humacyte 10-Q on SEC EDGAR.